阅读说明：本技术 一种冠突散囊菌制品及其应用 (Eurotium cristatum product and application thereof ) 是由 范代娣 董杨芳 段志广 宇文伟刚 严建亚 于 2020-08-20 设计创作，主要内容包括：本发明提供一种冠突散囊菌制品,所述冠突散囊菌制品包括冠突散囊菌和药学上可接受的辅料。本发明还提供了所述冠突散囊菌制品在制备预防、治疗脑血栓的药物中的应用；以及所述冠突散囊菌制品在降低血液中总胆固醇含量、三酰甘油含量、丙二醛含量、血液粘度、脑血管的通透性、或提高超氧化物歧化酶活性中的应用。本发明的冠突散囊菌制品能够抑制血栓的形成,使血液中的总胆固醇和三酰甘油的含量、血液粘度、脑血管的通透性及丙二醛水平降低,提高超氧化物歧化酶活性活性,对脑血栓具有一定的预防或者治疗作用。与现有技术相比,无毒副作用,见效快,疗效好,为脑血栓疾病提供了一种新的治疗思路,具有广阔的应用前景。(The invention provides a eurotium cristatum product, which comprises eurotium cristatum and pharmaceutically acceptable auxiliary materials. The invention also provides the application of the eurotium cristatum product in preparing the medicines for preventing and treating cerebral thrombosis; and the application of the eurotium cristatum product in reducing the total cholesterol content, the triacylglycerol content, the malondialdehyde content, the blood viscosity and the permeability of cerebral vessels in blood or improving the activity of superoxide dismutase. The eurotium cristatum product can inhibit the formation of thrombus, reduce the content of total cholesterol and triacylglycerol in blood, blood viscosity, permeability of cerebral vessels and malondialdehyde level, improve the activity of superoxide dismutase, and has certain prevention or treatment effect on cerebral thrombosis. Compared with the prior art, the traditional Chinese medicine composition has no toxic or side effect, takes effect quickly, has good curative effect, provides a new treatment idea for cerebral thrombosis diseases, and has wide application prospect.)

1. A Eurotium cristatum product is characterized by comprising Eurotium cristatum and pharmaceutically acceptable auxiliary materials.

2. The Eurotium cristatum preparation according to claim 1, wherein the classification of Eurotium cristatum is as Eurotium cristatum with a preservation number of CGMCC NO. 15398.

3. The Eurotium cristatum product according to claim 1, wherein the Eurotium cristatum is a tea-derived Eurotium cristatum.

4. The Eurotium cristatum product according to any one of claims 1-3, wherein the Eurotium cristatum is one or a combination of Eurotium cristatum hyphae and Eurotium cristatum spores.

5. The Eurotium cristatum product according to claim 4, wherein the Eurotium cristatum hyphae are in a wall-broken state, and the Eurotium cristatum spores are in a wall-broken state.

6. The Eurotium cristatum preparation according to any one of claims 1 to 5, wherein the Eurotium cristatum preparation is an oral preparation or an injection.

7. The Eurotium cristatum preparation according to claim 6, wherein the oral preparation is a tablet, a capsule or a granule.

8. The Eurotium cristatum preparation according to claim 6, wherein the pharmaceutically acceptable excipients comprise pharmaceutically acceptable carriers, excipients and diluents.

9. Use of the Eurotium cristatum preparation of any one of claims 1-8 in the preparation of a medicament for preventing and treating cerebral thrombosis.

10. Use of the Eurotium cristatum preparation according to any one of claims 1 to 8 for reducing the total cholesterol level, the triacylglycerol level, the malondialdehyde level, the blood viscosity, the permeability of cerebral vessels, or for increasing the activity of superoxide dismutase in blood.

Technical Field

The invention belongs to the technical field of biological agents, and particularly relates to a eurotium cristatum product and application thereof.

Background

Cerebral thrombosis is one of three killers causing human death as a serious ischemic cerebrovascular disease, and poses a fatal threat to human health. Epidemiological data show that the incidence rate of cerebral thrombosis accounts for more than 80 percent of the total incidence rate of cerebrovascular diseases. The morbidity and mortality of cerebral thrombosis in the country has been on an increasing trend for nearly a hundred years. Cerebral thrombosis is a common cerebral disease, and is mainly characterized in that atherosclerosis of a main artery or a branch cortical artery of a brain causes thickening, narrowing and blocking of a vessel wall, or thrombosis is formed on the basis of the atherosclerosis, so that the local blood flow of the brain is reduced, the blood supply is interrupted, and cerebral tissues are subjected to ischemia and hypoxia and are softened and necrotized to form lesions. The early treatment of cerebral thrombosis has important significance for reducing the fatality rate of middle-aged and elderly people, reducing complications and sequelae and recovering various functions of the body of the middle-aged and elderly people. Therefore, how to effectively prevent and treat cerebral thrombosis diseases is always the focus of attention in the medical field.

At present, the clinical treatment of cerebral thrombosis diseases generally adopts thrombolytic therapy, and infarction is relieved mainly through thrombolysis. The existing treatment medicines are single in effect, a plurality of medicines are often required to be combined for treatment, but the quality is difficult to control, the medication risk is high, and symptoms such as cerebral hemorrhage and the like are more likely to be caused. The high-curative-effect medicine is accompanied by adverse toxic and side effects, so that the safety risk exists; the medicine for ensuring the safety has the defects of poor curative effect, slow effect and the like. In addition, due to the complexity and specificity of the disease, the treatment course is long, and the treatment time is long, so that the application of the disease in the market has certain limitation. Therefore, the development of a novel, safe and effective medicament for preventing or treating cerebral thrombosis diseases is urgent.

Disclosure of Invention

Aiming at the defects in the prior art, the invention provides a eurotium cristatum product which can inhibit the formation of thrombus, reduce the content of total cholesterol and triacylglycerol in blood, the blood viscosity, the permeability of cerebral vessels and the level of malondialdehyde, improve the activity of superoxide dismutase and has certain prevention or treatment effect on cerebral thrombosis.

Specifically, the invention relates to the following technical scheme:

1. a Eurotium cristatum product is characterized by comprising Eurotium cristatum and pharmaceutically acceptable auxiliary materials.

2. The Eurotium cristatum preparation according to item 1, wherein the classification of Eurotium cristatum is as CGMCC No. 15398.

3. The Eurotium cristatum product according to item 1, characterized in that the Eurotium cristatum is a tea-derived Eurotium cristatum.

4. The Eurotium cristatum product according to any one of items 1 to 3, wherein the Eurotium cristatum is one or a combination of Eurotium cristatum hyphae and Eurotium cristatum spores.

5. The Eurotium cristatum product according to item 4, characterized in that the Eurotium cristatum hyphae is in a wall-broken state, and the Eurotium cristatum spores are in a wall-broken state.

6. The Eurotium cristatum preparation according to any one of items 1 to 5, wherein the Eurotium cristatum preparation is an oral preparation or an injection.

7. The Eurotium cristatum preparation according to item 6, wherein the oral preparation is a tablet, a capsule or a granule.

8. The Eurotium cristatum preparation according to item 6, wherein the pharmaceutically acceptable excipients comprise pharmaceutically acceptable carriers, excipients and diluents.

9. An application of the Eurotium cristatum product of any one of items 1-8 in preparing a medicament for preventing and treating cerebral thrombosis.

10. Use of the Eurotium cristatum preparation according to any one of items 1 to 8 for reducing the total cholesterol level, the triacylglycerol level, the malondialdehyde level, the blood viscosity, the permeability of cerebral vessels, or increasing the activity of superoxide dismutase in blood.

The eurotium cristatum product can inhibit the formation of thrombus, reduce the content of total cholesterol and triacylglycerol in blood, blood viscosity, permeability of cerebral vessels and malondialdehyde level, improve the activity of superoxide dismutase, and has certain prevention or treatment effect on cerebral thrombosis. Compared with the prior art, the traditional Chinese medicine composition has no toxic or side effect, takes effect quickly, has good curative effect, provides a new treatment idea for cerebral thrombosis diseases, and has wide application prospect.

Detailed Description

The present invention is further illustrated by the following examples, which are intended to be purely exemplary of the invention and are not intended to be limiting.

Unless defined otherwise, technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art. Although methods and materials similar or equivalent to those described herein can be used in experimental or practical applications, the materials and methods are described below. In case of conflict, the present specification, including definitions, will control, and the materials, methods, and examples are illustrative only and not intended to be limiting. The present invention is further illustrated by the following examples, which are not intended to limit the scope of the invention.

The invention provides a eurotium cristatum product, which comprises eurotium cristatum and pharmaceutically acceptable auxiliary materials.

In a specific embodiment, the Eurotium cristatum is classified and named as Eurotium cristatum, which is deposited in China general microbiological culture Collection center (CGMCC) at 4 and 2 days 2018 with the preservation number of CGMCC NO.15398 and the preservation address of Beijing Shang Yang Kong Xilu No.1 Hospital No. 3.

In a specific embodiment, the eurotium cristatum is fusca derived from fu tea.

In a specific embodiment, the Eurotium cristatum in the preparation of the present invention is one or a combination of Eurotium cristatum hyphae and Eurotium cristatum spores. The strain can be Eurotium cristatum hyphae, Eurotium cristatum spores, or Eurotium cristatum hyphae and Eurotium cristatum spores in any proportion.

The Eurotium cristatum hyphae and Eurotium cristatum spores can be in a wall-broken state after being treated by a physical, biological or chemical method, and can also be in a non-wall-broken state without being treated. In a preferred embodiment, the Eurotium cristatum hyphae are in a wall-broken state, and the Eurotium cristatum spores are in a wall-broken state. The physical, biological and chemical treatment for breaking cell walls refers to the wall breaking method commonly adopted by the technical personnel in the field, such as: high-pressure homogenizing, ultrasonic wall breaking, biological enzyme wall breaking, acid-base wall breaking, etc.

The pharmaceutically acceptable auxiliary materials comprise pharmaceutically acceptable carriers, excipients and diluents. They are compatible with the active ingredient. The pharmaceutically acceptable excipients are well known to those skilled in the art and may be, for example, magnesium stearate, sodium carboxymethylcellulose, microcrystalline cellulose or sodium starch glycolate.

In a specific embodiment, the Eurotium cristatum preparation is an oral preparation or an injection. The oral preparation is hard capsule, soft capsule, sustained-release capsule, sugar-coated tablet, powder, granule, dripping pill, water-honeyed pill, syrup or oral liquid; the injection is in a solution type, a suspension type, an emulsion type or freeze-dried powder type.

In a preferred embodiment, the eurotium cristatum preparation is an oral formulation. In still further preferred embodiments, the oral dosage form is a tablet, capsule or granule.

The invention also provides the application of the eurotium cristatum product in preparing medicines for preventing and treating cerebral thrombosis diseases.

The invention also provides the application of the eurotium cristatum product in reducing the total cholesterol content, the triacylglycerol content, the malondialdehyde content, the blood viscosity, the permeability of cerebral vessels or increasing the activity of superoxide dismutase in blood.

The invention is described generally and/or specifically for the materials used in the tests and the test methods, in the following examples,% means wt%, i.e. percent by weight, unless otherwise specified. The reagents or instruments used are not indicated by the manufacturer, and are all conventional reagent products or conventional laboratory instruments which are commercially available.

The following is a specific implementation of the present invention, and the examples are presented to facilitate a further understanding of the invention without limiting the claims and core content of the invention.